Cargando…
In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development
Mu opioid receptor (MOPr) agonists are well-known and frequently used clinical analgesics but are also rewarding due to their highly addictive and often abusive properties. This may lead to opioid use disorder (OUD) a disorder that effects millions of people worldwide. Therefore, novel compounds are...
Autores principales: | Lee, Alex S., Tiwari, Suchi, Bishop, Isabel, Matossian, Vartan, Romaneschi, Nicole, Miyazaki, Takahiro, VanderVeen, Laurie, Zalevsky, Jonathan, DeFea, Kathryn, Cahill, Catherine M., Walwyn, Wendy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915576/ https://www.ncbi.nlm.nih.gov/pubmed/35295409 http://dx.doi.org/10.3389/fpain.2021.695962 |
Ejemplares similares
-
SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain
por: Markman, John, et al.
Publicado: (2019) -
Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018) -
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
por: Dixit, Neha, et al.
Publicado: (2021) -
Editorial: Opioids in the time of the COVID-19 pandemic: from cellular mechanisms to public health policy
por: John, Scott, et al.
Publicado: (2023) -
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
por: Charych, Deborah, et al.
Publicado: (2017)